Opinion | ‘It’s a Disservice to Dr. Fauci’: What We Heard This Week
“It’s a disservice to Dr. Fauci that they felt this was necessary.” — Georges Benjamin, MD, executive director of the American Public Health Association, discussing former President Joe Biden’s decision to preemptively pardon Anthony Fauci, MD.
“Not all depressive symptoms are created equal.” — Jennifer Gatchel, MD, PhD, of Massachusetts General Hospital in Boston, on the relationship between amyloid pathology and depressive symptoms in adults without dementia.
“It doesn’t radically change things right now, but it’s a multi-front war, and we consider this a definite victory.” — Robert McNamara, MD, of Temple University in Philadelphia, on a private equity firm reaching a settlement with the Federal Trade Commission on a potential antitrust case.
“I’m handing it to pharmacists and saying ‘Give the patient the best deal on one of these’.” — Marvin Konstam, MD, of Tufts Medical Center in Boston, on choosing an SGLT2 inhibitor to reduce heart failure.
“This is a concerning precedent that public health messages won’t be left to public health professionals and experts, and instead will be potentially controlled by politicians.” — Sonja Rasmussen, MD, a former editor of Morbidity and Mortality Weekly Report, on the publication missing a week under the Trump administration’s federal health communications pause.
“If TikTok goes away, there’s probably going to be a temporary vacuum where misinformation is going to become even more rampant on these platforms.” — Zachary Rubin, MD, a pediatric allergist near Chicago, on the impact of a potential ban of the popular app.
“We start looking for thyroid cancer and, when we look for it, we find it.” — Rozalina McCoy, MD, MS, of the University of Maryland School of Medicine in Baltimore, explaining why more thyroid cancers are found soon after starting a GLP-1 receptor agonist.
“Mindfulness should be strongly considered for patients experiencing residual cravings after starting buprenorphine.” — Zev Schuman-Olivier, MD, of the Cambridge Health Alliance in Massachusetts, on benefits of mindfulness training for people with opioid use disorder.
“We don’t understand some of the sex-based differences that exist.” — Stephanie Faubion, MD, of the Mayo Clinic in Jacksonville, Florida, discussing a study that did not find a link between postmenopausal hormone therapy and glioma risk in women.
